StemCell Therapy

Mesoblast limited (MESO) is near the top in its industry group according to InvestorsObserver. MESO gets an overall rating of 82. That means it scores higher than 82 percent of stocks. Mesoblast limited gets a 95 rank in the Biotechnology industry. Biotechnology is number 10 out of 148 industries.

Finding the best stocks can be tricky. It isnt easy to compare companies across industries. Even companies that have relatively similar businesses can be tricky to compare sometimes. InvestorsObservers tools allow a top-down approach that lets you pick a metric, find the top sector and industry and then find the top stocks in that sector.

Our proprietary scoring system captures technical factors, fundamental analysis and the opinions of analysts on Wall Street. This makes InvestorsObservers overall rating a great way to get started, regardless of your investing style. Percentile-ranked scores are also easy to understand. A score of 100 is the top and a 0 is the bottom. Theres no need to try to remember what is good for a bunch of complicated ratios, just pay attention to which numbers are the highest.

Mesoblast limited (MESO) stock is trading at $16.61 as of 10:30 AM on Friday, Apr 24, an increase of $10.16, or 157.52% from the previous closing price of $6.45. The stock has traded between $14.33 and $20.57 so far today. Volume today is above average. So far 12,327,011 shares have traded compared to average volume of 428,508 shares.

To screen for more stocks like MESO click here.

Go here to read the rest:
Where Does Mesoblast limited (MESO) Stock Fall in the Biotechnology Field? - InvestorsObserver

This entry was posted on April 24, 2020 at 5:49 pm and is filed under Biotechnology. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed. |